Bispecific Antibodies Latch Onto Advances – Module 1

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (1 of 5 Modules)

This activity provides an overview of data for new and emerging T-cell directed bispecific antibodies in the management of hematologic malignancies, with a focus on multiple myeloma.

0.50 CE Credit(s)
Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze available data on bispecific antibodies for the treatment of multiple myeloma

Activity Faculty

Usmani, Saad-Faculty Headshot-135x135

Saad Z. Usmani, MD, MBA, FACP

Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources